企業概要
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that facilitates connections between patients and licensed healthcare professionals across the United States, United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and other international markets. The company functions within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, indicating its focus on producing and distributing specialized pharmaceutical products and generics. This entity employs approximately 2,442 individuals and holds a market capitalization of $4.50 billion, while generating an annual revenue of $2.35 billion. These valuation metrics suggest that the market assigns a significant premium to the company's revenue base, reflecting investor confidence in its scalable business model and established presence in the direct-to-consumer healthcare space.
財務健全性
The company reported a trailing twelve-month revenue of $2.35 billion, with net income reaching $128.37 million and EBITDA standing at $175.66 million. The substantial disparity between the $2.35 billion in revenue and the $128.37 million in net income highlights a cost structure where operating expenses, including cost of goods sold and administrative costs, absorb a significant portion of gross receipts before reaching the bottom line. Free cash flow for the period amounted to $110.51 million, which demonstrates the company's ability to generate cash after capital expenditures, thereby providing financial flexibility for operational investments or potential acquisitions. Profitability is characterized by a gross margin of 73.8%, indicating high efficiency in production and supply chain management relative to sales prices; however, the operating margin sits at 2.7%, suggesting that significant overhead costs are incurred to run the platform, while the profit margin of 5.5% reflects the final net profitability available to shareholders. The balance sheet shows a cash balance of $577.49 million against total debt of $1.12 billion, resulting in a debt-to-equity ratio of 207.16%, which characterizes a highly leveraged financial position rather than a conservative one. Despite the high leverage, the current ratio of 1.90 indicates that the company holds sufficient current assets to cover its short-term liabilities nearly twice over, ensuring adequate short-term liquidity. Return on Equity stands at 25.2% and Return on Assets is 5.3%, metrics that collectively reveal that management is effectively utilizing shareholder equity to generate substantial returns, even while managing a complex asset base with significant debt obligations.
バリュエーション評価
The stock carries a P/E ratio of 38.73 on a trailing twelve-month basis, while the forward P/E ratio is 13.91, implying that the market expects a significant expansion in earnings in the coming years to justify the current high multiple. The price-to-book ratio is 8.30, indicating that the company trades at a substantial premium relative to its tangible book value, which often reflects intangible assets like brand equity or proprietary technology that are not fully captured on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 1.92 and an EV/EBITDA of 28.72 further suggest that investors are willing to pay a premium for revenue growth and earnings potential, despite the high debt load. The stock has traded between a 52-week low of $13.74 and a 52-week high of $70.43, illustrating a wide trading range that captures significant market volatility over the past year. With a beta of 2.31, the stock exhibits high sensitivity to market movements, meaning its price volatility is more than twice that of the broader market, posing higher risk for risk-averse investors.
Growth & Income
Revenue growth year-over-year has accelerated to 28.4%, whereas earnings growth year-over-year declined by 17.4%, indicating that the company is currently prioritizing top-line expansion over immediate earnings accretion, likely due to heavy reinvestment in sales and marketing or operational scaling. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which signifies that all net income is retained within the business to fund growth initiatives and reduce the substantial debt load rather than being distributed to shareholders. This reinvestment strategy is consistent with the company's high growth rate in revenue but contrasts with the decline in earnings, suggesting a temporary phase of profitability compression during the scaling period. Overall, the growth and income profile presents a high-growth, non-dividend yielding equity with significant leverage, where value creation depends heavily on the successful transition of earnings growth to match revenue expansion in future periods.